MEI Pharma IncFind Ratings Reports
MEI PHARMA INC's gross profit margin for the second quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though it increased sales and net income significantly, the company was unable to grow at a faster pace than its industry competitors. MEI PHARMA INC is extremely liquid. Currently, the Quick Ratio is 16.61 which clearly shows the ability to cover any short-term cash needs. MEIP managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has increased by 6.29% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY17||Q2 FY16|
|Net Sales ($mil)||17.2||0.0|
|Net Income ($mil)||11.89||-5.1|
|Balance Sheet||Q2 FY17||Q2 FY16|
|Cash & Equiv. ($mil)||55.15||53.79|
|Total Assets ($mil)||58.21||55.02|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q2 FY17||Q2 FY16|
|Gross Profit Margin||89.79||0.0|
|Return on Assets||-6.05||-44.19|
|Return on Equity||-6.42||-47.08|
|Debt||Q2 FY17||Q2 FY16|
|Share Data||Q2 FY17||Q2 FY16|
|Shares outstanding (mil)||36.77||34.16|
|Div / share||0.0||0.0|
|Book value / share||1.49||1.51|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||162408.0||300588.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.32 indicates a significant discount versus the S&P 500 average of 3.06 and a significant discount versus the industry average of 10.06. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, MEI PHARMA INC proves to trade at a discount to investment alternatives within the industry.
|MEIP NM||Peers 38.69||MEIP NM||Peers 44.11|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
MEIP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
MEIP's P/CF is negative making the measure meaningless.
|MEIP NM||Peers 22.54||MEIP NA||Peers 0.48|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
MEIP is trading at a significant premium to its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|MEIP 1.32||Peers 10.06||MEIP 81.95||Peers -14.63|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
MEIP is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
MEIP is expected to have an earnings growth rate that significantly exceeds its peers.
|MEIP 3.96||Peers 111.01||MEIP NA||Peers 455.32|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
MEIP is trading at a significant discount to its industry on this measurement.
Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.
The growth rate for MEIP is not available.